REDWOOD CITY, Calif., May 11, 2020 -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will present at the UBS Virtual Healthcare.
Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Companies in the news are: ALT, BIG, W, CDXS
Codexis (CDXS) delivered earnings and revenue surprises of -66.67% and -11.41%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
John Nicols has been the CEO of Codexis, Inc. (NASDAQ:CDXS) since 2012. This analysis aims first to contrast CEO...
Ladies and gentlemen, thank you for standing by, and welcome to the first-quarter 2020 Codexis earnings conference call. This is Bruce Voss with LHA. Thank you all for participating in today's Codexis call to discuss first-quarter 2020 financial results and recent business progress.
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Codexis (NASDAQ:CDXS) on Monday, setting a price target of $21, which is approximately 71.71% above the present share price of $12.23.
2019 total revenues increased 13% to $68.5 million with product revenue up 15% and R&D revenue up 11% Ten customers contributed more than $1 million each to 2019.
Codexis, Inc., a leading protein engineering company and developer of novel biotherapeutics, announces the signing of a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (Takeda) for the research and development of novel gene therapies for certain disease indications, including the treatment of lysosomal storage disorders and blood factor deficiencies.
Codexis, Inc., a leading protein engineering company and developer of novel biotherapeutics, announces the appointment of Stefan Lutz, Ph.D. as Senior Vice President, Research and Karl A. Schoene, Ph.D. as Senior Vice President, Development & Operations, effective immediately. Both positions are newly created and both report to Codexis President and CEO John Nicols.
REDWOOD CITY, Calif., May 27, 2020 -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will participate in two virtual investment.
REDWOOD CITY, Calif., Feb. 20, 2020 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report 2019 fourth quarter and full year.
REDWOOD CITY, Calif., Feb. 25, 2020 -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will present at two upcoming investment.
REDWOOD CITY, Calif., April 30, 2020 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report first quarter 2020 financial results.
Q1 2020 Codexis Inc Earnings Call
Q4 2019 Codexis Inc Earnings Call
The company's largest source of revenue will be affected by the pandemic, but there appears to be a silver lining.
R&D revenue increased 26% to $9.6 million fueled by the Novartis and Takeda strategic collaborations Withdraws 2020 financial guidance due to uncertainty of COVID-19.
Codexis, Inc., a leading protein engineering company and developer of novel biotherapeutics, announces achievement of the Wave 2 milestone associated with the CodeEvolver® platform technology transfer and license agreement with Novartis Pharma AG (“Novartis”) that was executed in May, 2019. Completion of Wave 2 deliverables confirms that Novartis is now equipped to begin to practice the CodeEvolver® platform technology at its designated site. “It is terrific to see the continued progress establishing Novartis as our newest CodeEvolver® licensing partner,” stated John Nicols, Codexis President and CEO.
It's been a sad week for Codexis, Inc. (NASDAQ:CDXS), who've watched their investment drop 17% to US$11.57 in the week...